

1 **Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after**
2 **COVID-19 vaccination in ALSPAC participants**

3
4 Holly E. Baum ^{>1,2}, Marianna Santopaolo ^{>1}, Ore Francis ^{1,3}, Emily Milowdowski ³, Katrina
5 Entwistle ³, Elizabeth Oliver ^{1,2}, Benjamin Hitchings ^{1,2}, Divya Diamond ¹, Amy C. Thomas ⁴, Ruth
6 E. Mitchell ⁴, Milla Kibble ^{4,5,6}, Kapil Gupta ⁷, Natalie Di Bartolo ⁷, Paul Klenerman ⁸, Anthony
7 Brown ⁹, Begonia Morales-Aza ^{1,2}, Jennifer Oliver ^{2,4}, Imre Berger ⁷, Ash M. Toye ⁷, Adam Finn
8 ^{1,2,4,10}, Anu Goenka ^{1,2,4,10}, Andrew D. Davidson ¹, Susan Ring ^{4, 11}, Lynn Molloy ⁴, Melanie
9 Lewcock ⁴, Kate Northstone ⁴, Firona Roth ⁴, Nicholas J. Timpson ^{4,11}, Linda Wooldridge ^{^3}, Alice
10 Halliday ^{^1,2}, Laura Rivino ^{*^1}

11
12 ¹ School of Cellular and Molecular Medicine, Faculty of Health and Life Sciences, University of
13 Bristol, Bristol, UK

14 ² Bristol Vaccine Centre, University of Bristol, Bristol, UK

15 ³ Bristol Veterinary School, Faculty of Health and Life Sciences, University of Bristol, Bristol, UK

16 ⁴ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

17 ⁵ Department of Applied Mathematics & Theoretical Physics, University of Cambridge,
18 Cambridge, UK

19 ⁶ Department of Twin Research and Genetic Epidemiology, King's College London, London, UK

20 ⁷ School of Biochemistry, Faculty of Health and Life Sciences, University of Bristol, Bristol, UK

21 ⁸ Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, Oxford,
22 UK

23 ⁹ Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK

24 ¹⁰ Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for
25 Children, Bristol, UK

26 ¹¹ MRC Integrative Epidemiology Unit at University of Bristol, Bristol, UK

27

28 > **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
 > **First authors contributed equally**

29 ^ Senior authors contributed equally

30 * Corresponding author / Lead contact

31

32 Correspondence: Dr Laura Rivino (Laura.Rivino@bristol.ac.uk)

33

34 **SUMMARY**

35 Immunological memory to vaccination and viral infection involves coordinated action of B and T-
36 cells, thus integrated analysis of these two components is critical for understanding their
37 contributions to protection against breakthrough infections (BI). We investigated cellular and
38 humoral immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination in
39 participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). The magnitude
40 of antibody and T-cell responses following the second vaccine dose was associated with
41 protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in
42 infection-naïve controls. Youden's index thresholds for protection against BI were calculated for
43 all immune measures. Anti-Spike IgG (>666.4 BAU/mL) and anti-Nucleocapsid pan Ig (>0.1332
44 BAU/mL) thresholds combined were 100% specific and 83.3% sensitive for cases without BI over
45 8-months follow-up. Collectively these results point to the superior protective effect of hybrid
46 immunity and have implications for the design of next-generation COVID-19 vaccines.

47

48 **KEYWORDS**

49 ALSPAC, SARS-CoV-2, COVID-19, adaptive immunity, T-cells, antibodies, infection,
50 vaccination, hybrid immunity, breakthrough infection

51

52 **INTRODUCTION**

53 The COVID-19 pandemic caused substantive medical and socioeconomic burdens that continue
54 to affect the global population¹⁻⁴. Infection with severe acute respiratory syndrome coronavirus 2

55 (SARS-CoV-2) presents as a broad spectrum of clinical manifestations from asymptomatic or
56 mild infections, through to severe illness, and associated mortality^{5,6}. The rapid deployment of
57 COVID-19 vaccines proved instrumental in reducing SARS-CoV-2 infections and subsequent
58 hospitalisations and deaths, however vaccine effectiveness wanes over time⁷⁻⁹. Breakthrough
59 infections (BIs) are well documented and are influenced not only by waning immunity, but also
60 the evolution of novel viral variants¹⁰⁻¹³.

61
62 A broad repertoire of antibody and cellular responses are elicited by SARS-CoV-2 infection¹⁴⁻¹⁶
63 and COVID-19 vaccination¹⁷⁻¹⁹. Evidence for anti-Spike (S) IgG and neutralizing antibody titres
64 as correlates of protection (COPs) against SARS-CoV-2 infection and severe disease have been
65 demonstrated in COVID-19 vaccine trials^{20,21}, and studies of BIs^{12,13}. Additionally, both systemic
66 and mucosal IgA have been implicated in protection against infection²²⁻²⁴. SARS-CoV-2-specific
67 T-cell responses are more durable than antibodies²⁵, and may therefore be important for
68 protection longer-term, and against novel variants which can evade antibody-mediated
69 immunity^{26,27}. Furthermore, cross-reactive T-cells can enhance infection- and vaccine-mediated
70 responses²⁸ and induce abortive infections in highly exposed individuals²⁹.

71
72 Anti-viral immune memory responses are determined by the coordinated action of antibodies and
73 T-cells targeting the virus, and an integrated analysis of these two components is therefore critical
74 for understanding their contributions to protection. In this study we investigate the cellular and
75 humoral responses to SARS-CoV-2 after infection and/or vaccination in participants from the
76 Avon Longitudinal Study of Parents and Children (ALSPAC). We further address the role of
77 antibodies and T-cells in providing protection against BI in participants with hybrid immunity,
78 induced by a combination of SARS-CoV-2 infection and COVID-19 vaccination, as compared to
79 those with vaccine-induced immunity alone.

80

81

82 RESULTS

83 *Study design and recruitment*

84 This study was open to ALSPAC participants of the G0 (48-70 years) and G1 (29-30 years)
85 generations. 377 participants enrolled, and attended clinics in December 2020, March 2021, and
86 June 2021 (Figure 1). Study participants were 59.2% female, 97.8% white, and 58.5% G1
87 generation (Table S1). Participants were selected from a cohort of 4819 individuals who had a
88 valid SARS-CoV-2 antibody lateral flow test (LFT) result in October 2020. LFT anti-S IgG
89 positivity rates were 3.1% and 5.8% in the G0 and G1 generations respectively (Figure 1). These
90 results were used as an initial screen to identify participants with and without a likely history of
91 SARS-CoV-2 infection for inclusion in this study³⁰.

92
93 To validate the LFT results, serum samples from clinic 1 were screened for SARS-CoV-2-specific
94 anti-S and anti-Nucleocapsid (N) antibodies using in-house ELISAs. Participants were defined
95 as 'cases' if they had a previous PCR-confirmed SARS-CoV-2 infection and/or were positive on
96 the anti-N or anti-Spike ELISAs (Figure 2A). The remaining seronegative individuals with no
97 history of COVID-19 are herein referred to as 'controls'. Clinic 1 samples were taken prior to
98 participants being vaccinated as part of the UK COVID-19 vaccination programme. Of those who
99 provided information on their vaccination status, 64.0% had received at least one dose by clinic
100 2, rising to 97.0% by clinic 3 (Figure 1). Data was therefore analysed relative to the number of
101 COVID-19 vaccinations received (Figure S1), rather than chronologically by clinic, as this was
102 deemed to be the dominant variable influencing immune responses.

103

104 *Antibody responses to COVID-19 vaccination*

105 At baseline, anti-S and anti-N pan Ig levels were higher in cases compared to controls ($P \leq 0.0001$;
106 Figure 2A). A vaccine-induced increase in anti-S pan Ig was observed in both groups. Following
107 the second dose, all participants had anti-S pan Ig levels above the assay positivity threshold.
108 However, the case group retained their baseline advantage with higher median titres. Rates of
109 new SARS-CoV-2 infections between clinics 1-3 were low, with four individuals in the control

110 group reporting a positive PCR test. Consistent with this observation, a small increase in median
111 anti-N pan Ig was observed after the first dose ($P=0.0471$), which plateaued after dose 2 (Figure
112 2A). This was predominantly driven by ≥ 2 -fold increases in anti-N pan Ig levels in a small minority
113 of participants (3/95; Figure S2). Anti-N pan Ig levels in the case group remained stable
114 throughout.

115
116 Anti-S IgG in serum and saliva showed similar kinetics to serum anti-S pan Ig responses. Post-
117 vaccination anti-S IgG levels in the two sample types were very strongly correlated after the first
118 ($r_s=0.858$, $P\leq 0.0001$) and second ($r_s=0.809$, $P\leq 0.0001$) doses (Figure 2C). Serum
119 pseudoneutralising antibody titres in the case group increased in response to the first vaccination,
120 then remained stable following the second dose (Figure 2B). A strong positive correlation
121 between anti-S IgG and pseudoneutralising antibody titre was observed following each dose
122 ($r_s=0.784$, $P\leq 0.0001$ / $r_s=0.656$, $P\leq 0.0001$; Figure S3).

123
124 Pre-vaccination anti-S IgA in serum and saliva was higher in cases than controls (Figure 2D).
125 Serum anti-S IgA increased in both groups after the first dose, whilst median salivary anti-S IgA
126 levels were not boosted by vaccination. There was therefore only a weak correlation between
127 the two measures post-vaccination ($r_s=0.355$, $P\leq 0.0001$ / $r_s=0.246$, $P=0.0045$). Recipients of
128 mRNA vaccines had higher median serum anti-S IgG and IgA levels than recipients of the
129 adenoviral vector based ChAdOx1 (Figure S4).

130

131 ***T-cell responses to COVID-19 vaccination***

132 T-cell responses targeting SARS-CoV-2 S1/S2, N, Membrane (M), Envelope (E), non-structural
133 proteins (NSP3-16) and accessory proteins (ORF3, ORF6, ORF7 and ORF8) were measured by
134 IFN- γ ELISpot (Figure S5A/B). Baseline S-specific IFN- γ responses were lower in controls
135 compared to cases ($P\leq 0.0001$; Figure 2E). In both groups, S-specific T-cells increased after the
136 first vaccination and then remained stable. In the case group, T-cell responses to N, M and
137 NSP3B were not boosted by vaccination while those to NSP 1+2 increased after vaccination. In

138 contrast, increased T-cell responses to M ($P \leq 0.0001$), N ($P = 0.0175$), and NSP3B ($P = 0.0091$)
139 were observed in control participants after dose 2 compared to baseline (Figure 2E). T-cell
140 responses to NSP3-16, ORF3, ORF7 and ORF8, remained stable following vaccination (Figure
141 S5A/B).

142

143 ***Magnitude and quality of T-cell responses to SARS-CoV-2 infection***

144 The magnitude and functional phenotype of the CD4⁺ and CD8⁺ T-cell response targeting S, N,
145 M and NSP3B proteins were analysed in cases, prior to vaccination. Production of IFN- γ , TNF- α ,
146 MIP1 β , IL-2 and degranulation (CD107a) by SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells was
147 measured by ICS. A representative gating strategy is shown in Figure S6. Responses were
148 comprised of monofunctional and polyfunctional T-cells producing 1 or >1 effector functions
149 respectively, with monofunctional T-cells dominating both the CD4⁺ and CD8⁺ T-cell response
150 (Figure 3; see Table S2 for statistical comparisons). Monofunctional SARS-CoV-2-specific CD4⁺
151 T-cells produced mainly TNF- α (S1=59.03%, S2=28.45%, M=25.7%, N=41.35%,
152 NSP3B=27.35%) and IFN- γ (S1=23.59%, S2=16.75%, M=35.39%, N=34.55%,
153 NSP3B=48.34%). The frequencies of CD4⁺ T-cells producing each cytokine were comparable
154 across proteins (Figure S7A). In contrast, CD107a was expressed at higher levels by CD4⁺ T-
155 cells targeting M (34.26%), compared to S1 (5.25%), S2 (5.23%), and N proteins (9.42%).
156 Polyfunctional CD4⁺ T-cells were mainly IFN- γ ⁺/TNF- α ⁺, IL-2⁺/TNF- α ⁺ and IFN- γ ⁺/IL-2⁺/TNF- α ⁺
157 (Figure 3A).

158

159 Similarly to CD4⁺ T-cells, cytokine production by CD8⁺ T-cells targeting the different SARS-CoV-
160 2 proteins was comparable while CD107a was expressed by a larger proportion of CD8⁺ T-cells
161 specific for M compared to other proteins (M=31.7%, S1=1.63%, S2=4.91%, N=3.52%,
162 NSP3B=4.27%) (Figure S7B). Polyfunctional CD8⁺ T-cells were mainly double or triple-cytokine
163 producing, including IFN- γ ⁺/TNF- α ⁺, CD107a⁺/TNF- α ⁺, MIP1 β ⁺/TNF- α ⁺, MIP1 β ⁺/IFN- γ ⁺ and
164 MIP1 β ⁺/IFN- γ ⁺/TNF- α ⁺. NSP3B-specific CD8⁺ T-cells displayed higher polyfunctionality (14.8%)
165 compared to those targeting S (S1=10.4%, S2=5.29%) or (N=5.33%) (Figure 3B; Figure S8A/B).

166

167 ***Association between post-vaccination immune responses and protection against SARS-***
168 ***CoV-2 BI***

169 We next investigated the relationship between the magnitude of antibody and T-cell responses
170 after the second vaccination, and protection against SARS-CoV-2 BI. The case and control
171 groups were subdivided based on self-reported questionnaire data detailing whether the
172 participant had a PCR/LFT-confirmed SARS-CoV-2 infection in the 8-months following the
173 sample collection period (July 2021 - March 2022; Figure 1). For this analysis, the case group
174 was updated to include two individuals who had PCR-confirmed SARS-CoV-2 infections between
175 clinics 1-3. BI rates were higher in the control group (42.4%) compared to the cases (30.8%). Of
176 the individuals who reported BIs, the median time since receiving a second vaccination, and the
177 proportion who received a third vaccination prior to infection, were comparable between cases
178 and controls (Table S3). Self-reported BIs were consistent with increased rates of LFT anti-N IgG
179 positivity detected in the wider ALSPAC cohort in the period from May 2021 (G1=14.8%;
180 G0=9.8%) to May 2022 (G1=67.1%; G0=50.3%; Figure 1).

181

182 In participants without a history of COVID-19, there was no strong evidence of differences
183 between those who went on to experience a BI, compared to those who didn't, with respect to
184 the magnitude of immune variables measured (Figure S9A; Figure 4A). Conversely, previously
185 infected participants showed evidence of clustering by subsequent infection status (Figure 4B).
186 Higher levels of anti-S IgG in serum and saliva, pseudoneutralising antibody, and anti-S IgA in
187 serum as well as S1-specific T-cell responses were observed in those with no reported BI (Figure
188 S9B). Similarly, high anti-N Pan Ig titres were associated with a decreased likelihood of re-
189 infection. The lack of vaccine-induced salivary IgA in this cohort was reflected in the poor
190 performance of this measure as a discriminator of future infection susceptibility.

191

192 To compare the effectiveness of individual markers for discriminating between cases who did or
193 didn't go on to be re-infected, ROC curves were plotted, and thresholds calculated using the

194 Youden's Index method to balance sensitivity and specificity (Figure S10). Anti-S IgG ≥ 666.4
195 BAU/mL in serum (SP=87.5%), or 0.547 BAU/mL in saliva (SP=75.0%), provided 94.4%
196 sensitivity for identifying participants who didn't report BIs (Figure 4). Specificity was improved to
197 100.0% by combining serum or saliva S-specific IgG, and N-specific pan Ig, thresholds
198 (SP=100%, SE=83.3%). Combining S-specific serum IgG with IgA in serum or saliva, or with T-
199 cell responses, did not improve discrimination. Pseudoneutralising antibody ≥ 6165 units provided
200 a highly specific threshold (SP=100%) for identification of protected individuals, albeit with lower
201 sensitivity (SE=61.1%) than the S-specific IgG threshold (SE=94.4%).

202
203 The magnitude of T-cell responses to the S1 pool (SP=87.5%, SE=72.2%) provided a more
204 specific and sensitive marker of infection susceptibility than those to the S2 (SP=75.0%,
205 SE=66.67%) or N (SP 87.5%, SE=38.9%). Combining thresholds for T-cell S1 and N did not
206 improve performance compared to S1 alone. Conversely, combining T-cell S1 with N-specific
207 pan Ig offered improved specificity with no loss of sensitivity (SP=100%, SE=72.2%). The
208 performances of all threshold combinations are detailed in Figure S11.

209 210 ***Association between ICS responses to pre-vaccination SARS-CoV-2 infection and BI***

211 To determine whether specific features of the T-cell response to SARS-CoV-2 infections were
212 also a factor in determining risk of BI, pre-vaccination ICS responses were compared in cases
213 with and without a reported BI. Monofunctional CD4⁺ and CD8⁺ T cell responses were included
214 in these analyses as these were the predominant responses observed in these individuals. There
215 was no meaningful difference between the magnitude of S, N or NS3PB-specific T-cell responses
216 in the two groups (Figure 4C/D, Figure S8C/D). In contrast, participants who didn't report BIs
217 displayed higher magnitudes of SARS-CoV-2 M-specific CD4⁺ and CD8⁺ T-cells, and these were
218 skewed respectively towards production of IFN- γ ⁺ and CD107a (IFN- γ ⁺: 40.0%; CD107a: 35.7%;
219 Figure 4E), and CD107a and MIP1 β (CD107a: 42.4%; MIP1 β : 45.0%; Figure 4F), respectively.
220 However, including these ICS measures in the analysis did not improve the predictive ability of
221 thresholds generated using antibody and/or T-cell data alone.

222

223 **DISCUSSION**

224 Humoral and cellular immune responses to COVID-19 vaccination were measured in ALSPAC
225 participants with or without a history or serological evidence of SARS-CoV-2 infection. In those
226 with hybrid immunity, we demonstrate a correlation between the magnitude of responses
227 following the second vaccination and protection against BI. The combination of serum S-specific
228 IgG (>666.4 BAU/mL) and N-specific pan Ig (>0.1332 BAU/mL) thresholds identified those who
229 didn't report BIs with 100% specificity and 83% sensitivity. Our results suggest that hybrid
230 immunity to SARS-CoV-2 remains effective in protection from reinfection at >15 months post
231 infection and >8 months post second-dose vaccination. The reduced association in control
232 participants alludes to the importance of the greater quality and breadth of immune responses
233 elicited by SARS-CoV-2 infection compared to vaccination alone.

234

235 COVID-19 vaccination elicited robust serum anti-S IgG and IgA production in all participants, with
236 the case group retaining their baseline immunological advantage as observed in other studies³¹.
237 mRNA vaccination resulted in higher S-specific IgG and IgA compared to the viral vector
238 ChAdOx1, as previously reported³². However, neither vaccine type induced salivary IgA, even in
239 participants with a history of COVID-19 where vaccination has been suggested to boost infection-
240 primed responses^{22,33,34}. Reducing or eliminating transmission with vaccines capable of eliciting
241 mucosal immunity therefore remains a priority, and a number of candidates are currently in
242 development³⁵.

243

244 Consistent with recent papers, COVID-19 vaccines induced S-specific T-cell responses in all
245 participants³⁶⁻³⁸. An increase in the median frequency of T-cell responses to M, N, and NSP3B
246 was observed in the control group. This was predominantly driven by large increases to all target
247 antigens in a small number of participants, suggestive of SARS-CoV-2 infections in these
248 individuals during the study period. No parallel increases in serum anti-N pan Ig or saliva anti-S
249 IgA were observed. These participants with may therefore have experienced asymptomatic,

250 abortive SARS-CoV-2 infections which have been shown to boost T-cell responses in the
251 absence of seroconversion²⁹. Alternatively, these data could potentially suggest bystander T-cell
252 activation as a result of vaccination. Antigen-independent bystander activation of T-cells which
253 is likely driven by cytokines, has been widely reported during viral infection^{39,40}, however its
254 occurrence in the context of vaccination remains unclear^{41–45}.

255
256 Long-term protection against SARS-CoV-2 BI relies upon the durability of vaccine-induced
257 responses. Antibodies in particular have been shown to wane rapidly in the 6-months following
258 the primary and subsequent vaccine doses^{46–48}. This declining immunity, particularly in the
259 context of highly transmissible SARS-CoV-2 variants with reduced neutralising sensitivity,
260 increases BI rates^{8,10,49}. Anti-S IgG and neutralising antibody levels have been shown to
261 negatively correlate with the risk of SARS-CoV-2 infection and severe disease^{12,21,50–52}. In control
262 participants, we observed no evidence of difference in the magnitude of responses between
263 those who did and didn't experience BIs, and protective thresholds could therefore not be
264 defined. However, anti-S IgG ≥ 666.4 BAU/mL was associated with reduced incidence of BI in
265 those with a history of SARS-CoV-2 infection. This is consistent with the large Israeli COVID-19
266 family study (ICoFS) which proposed S-specific IgG >500 BAU/mL, and neutralising antibody
267 titres of >1024 , as thresholds of protection against SARS-CoV-2 Delta infection⁵³. IgG levels
268 above this were associated with an 11% probability of infection, and 1% probability of moderate
269 disease. ICoFS baseline measurements were taken shortly before infection and therefore their
270 lower threshold value is expected relative to our use of post-vaccination dose 2 titres that were
271 recorded months earlier. Serum anti-S IgA also associated with reduced BIs in our cohort, and
272 alongside mucosal IgA has previously been shown to correlate with protection against infection
273 independently of IgG²². BIs experienced shortly after primary vaccination correlated with lower
274 vaccine-induced IgA²², and in those who experienced infections serum IgA levels inversely
275 correlated with symptom duration⁵⁴. Increased S-specific T-cells also correlated with reduced BI
276 in our cohort, consistent with previous reports for both CD4⁺ and CD8⁺ responses^{55,56}.

277 Furthermore, the combination of high neutralizing antibodies and S-specific IFN- γ responses is
278 associated with protection against BI^{57,58}.

279
280 There is now mounting evidence that hybrid immunity affords more robust and sustained
281 protection against BI compared to vaccine-induced immunity alone^{46,59–62}. Consistent with this,
282 BI rates in our study were lower in cases (30.8%) compared to controls (42.4%). Both humoral
283 and cellular immune responses have been reported to be qualitatively superior in those who
284 experience SARS-CoV-2 infection prior to vaccination^{61,62}, and infection-derived immunity may
285 be particularly important in the context of BIs with novel variants^{23,63}. It is only SARS-CoV-2
286 infection that induces a significant and durable systemic IgA response⁴⁸, and COVID-19 vaccines
287 perform poorly at eliciting mucosal IgA³⁴. Additionally, the increased magnitude of neutralising
288 responses in hybrid immunity enhances the breadth of neutralising activity against divergent
289 variants of concern^{64,65}. Vaccine-induced Fc-receptor binding antibodies are also important for
290 the control and clearance of infection and have also been shown to be more abundant in those
291 with a history of COVID-19, with this difference persisting post-vaccination⁶¹.

292
293 Functional and phenotypic properties of SARS-CoV-2 adaptive immunity appear to differ in
294 response to SARS-CoV-2 infection and COVID-19 vaccination^{66,67}. A skewed T-helper (Th)1
295 SARS-CoV-2-specific T-cell response and higher percentages of IgG-expressing memory B-cells
296 were observed in vaccinated individuals compared to individuals who recovered from COVID-
297 19⁶⁸. In this study we assessed the functional and phenotypic features of SARS-CoV-2-specific
298 CD4⁺ and CD8⁺ T-cells in previously infected individuals prior to vaccination, and compared these
299 in individuals who subsequently did or did not experience BIs. We show trends towards higher
300 magnitudes of SARS-CoV2-specific CD8⁺ T-cells targeting S2, N, M and NSP3B in individuals
301 who do not develop BI, with differences being significantly higher only for M, suggesting a
302 protective role for these cells. Similarly, M-specific CD4⁺ T-cells are present at higher magnitudes
303 in individuals who do not develop BI compared to those that do. In addition, the former group
304 displays M-specific CD4⁺ T-cells mainly producing IFN- γ and CD107a, which suggests a

305 protective role of cytotoxic Th1-cells in COVID-19. These data highlight how a granular analysis
306 of CD4⁺/CD8⁺ T-cell responses may inform T-cell features associated with protection in COVID-
307 19. This is critical for an integrated definition (incorporating T-cells and antibodies) of
308 correlates/determinants of protective immunity to SARS-CoV-2 and potentially other viral
309 infections.

310

311 In addition to changing the quality of responses, SARS-CoV-2 infection primes the immune
312 system with a broader range of antigens than vaccination. Anti-N seropositivity was strongly
313 associated with protection against reported BIs in our cohort. This corroborates the conclusions
314 of other studies, with previous estimates suggesting that it afforded participants with
315 approximately 80% protection against SARS-CoV-2 re-infection for the subsequent 8-months⁶⁹.
316 In those experiencing BIs, anti-N seropositivity also associated with a shorter duration and
317 reduced viral load⁵⁴. Evidence suggests that COVID-19 vaccination drives differential responses
318 to subsequent SARS-CoV-2 infection, boosting those primed by the vaccine over new responses
319 to the broader repertoire of proteins in the virus^{54,70-72}. Seroconversion to N upon SARS-CoV-2
320 infection was observed at a higher rate in placebo vaccinated participants (93%) compared to
321 mRNA-1273 recipients (40%)⁷⁰. Additionally, SARS-CoV-2 BIs elicit anti-N IgG at significantly
322 lower rates in infection-naïve individuals compared to those with a history of pre-vaccination
323 COVID-19^{54,71,72}. This suggests that the order in which hybrid immunity is achieved may be
324 important.

325

326 SARS-CoV-2 LFT testing of a wider sample of ALSPAC participants highlighted an age-related
327 difference in anti-N positivity rates. By spring 2022, all UK adults had been offered 3 vaccine
328 doses, and this was reflected in comparable anti-S positivity rates of 93.0% and 96.0% in the
329 G0/G1 cohorts respectively. However, only 50.3% of the older generation had a positive anti-N
330 response compared to 67.1% of the younger adults. These values may underestimate SARS-
331 CoV-2 infection rates in the older generation due to the lower N-seroconversion rates in infections
332 occurring post-vaccination. However, they do accurately reflect a lack of potentially protective

333 anti-N antibodies in this population. Prioritising older adults for early vaccination, and
334 encouraging shielding behaviours, may therefore have consequences for the breadth and
335 durability of the immunity they obtain by reducing pre-vaccination infection rates, and overall N-
336 seroconversion. Rapid vaccination of this age group proved essential for reducing the rates of
337 severe disease and associated mortality, and on a population level these benefits are unlikely to
338 be outweighed by the benefits of a broader infection-primed response. Instead, this highlights
339 the importance of designing novel vaccines that prime responses to additional antigens to
340 generate more robust and sustained protection.

341

342 Our BI susceptibility analysis should be interpreted in the context of the limitations of our study
343 design. Firstly, the sample size was limited by those with available post-dose 2 vaccination
344 measures and may not be representative of the whole population. Secondly, with respect to the
345 BI rates in the case and controls groups, differences in exposure risk and test-seeking behaviours
346 which could not be measured or accounted for may have influenced outcomes. Key variables,
347 such as the proportion who received a booster vaccine, were however comparable between
348 groups. Thirdly, N-protein serology does not offer 100% sensitivity for detection of new SARS-
349 CoV-2 cases and therefore undetected infections during the study period could have resulted in
350 participants being mis-classified as controls for the BI analysis. Fourthly, samples were not
351 collected at the point of BI and therefore could not be confirmed virologically, nor the SARS-CoV-
352 2 sequences/variant lineages determined. The BI infection monitoring period covered the
353 boundary of Delta and Omicron being the predominant variants in circulation. For the purposes
354 of this analysis, all SARS-CoV-2 infections have been analysed together, but it is possible that
355 variant-specific thresholds for protection may differ. Fifthly, although we report correlations
356 between immune markers and susceptibility to future infection, we cannot exclude the possibility
357 that rather than being directly protective, some may act as proxies for undetermined variables
358 that weren't measured. Finally, sample size limitations prevented the stratification of the BI
359 analysis by vaccine type. However, this has previously been shown not to directly influence the
360 susceptibility to BIs. Instead, higher BI rates in ChAdOx1 recipients can be attributed to the lower

361 immunogenicity of ChAdOx1 resulting in participant IgG levels waning below protective
362 thresholds faster than in BNT162b2 recipients¹³.

363

364 In summary, the data generated here add detail to the evidence of broader immune responses
365 to infection and vaccination beyond the comparatively well-characterised anti-S IgG and
366 neutralising antibody levels as markers of protection against SARS-CoV-2 BIs. Additionally, our
367 findings support the notion that it is not only the magnitude of T-cell responses generated by
368 hybrid immunity that improves protection against BI, but also their breadth and quality. This
369 reinforces the need for next generation vaccines that elicit hybrid-mimicking immune responses
370 for more robust and sustained protection. Better understanding the immune markers correlated
371 with protection will also be important for the rapid validation of these new vaccines at a point in
372 the pandemic when placebo-controlled vaccine trials are no longer practical.

373

374

375

376 **ACKNOWLEDGEMENTS**

377 We are extremely grateful to all the families who took part in this study, the midwives for their
378 help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and
379 laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists
380 and nurses.

381

382 We wish to acknowledge the assistance of Dr Andrew Herman, Helen Rice, and the University
383 of Bristol Faculty of Health and Life Sciences Flow Cytometry Facility. This work was undertaken
384 with support of the Elizabeth Blackwell Institute (EBI) Mechanisms to Populations Research
385 Strand that promotes interdisciplinary research between fundamental bioscience and population
386 health. The support from the EBI and the University's Alumni and Friends funded the purchase
387 of the CTL ELISpot reader and ELISA microplate washer, and ELISpot peptide pools used in this

388 study. Thank you to the Bristol UNCOVER group for helpful discussions on assay development
389 and the interpretation of results.

390

391 **FUNDING**

392 This work was funded by UK Research and Innovation (UKRI) through the UKRI rapid response
393 call for COVID (MR/V028448/1). This work was supported by the Elizabeth Blackwell Institute,
394 University of Bristol, with funding from the Wellcome Trust ISSF3 (204813/Z/16/Z), and the
395 University's Alumni and Friends (LW, LR, AH, AD, AF and OF).

396

397 NJT is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT
398 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre
399 (BRC-1215-2001), the Medical Research Council (MRC) Integrative Epidemiology Unit
400 (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme
401 (C18281/A29019). MK is supported by the MRC (MR/W021315/1). MS is supported by the
402 Academy of Medical Sciences (Springboard Award SB007\100173).

403

404 The MRC and the Wellcome Trust (Grant ref: 217065/Z/19/Z) and the University of Bristol provide
405 core support for ALSPAC. This publication is the work of the authors; LR, AH, LW, HEB and MS
406 will serve as guarantors for the contents of this paper. A comprehensive list of grant funding is
407 available on the ALSPAC website ([http://www.bristol.ac.uk/alspac/external/documents/grant-
408 acknowledgements.pdf](http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf)). This research was specifically funded by the Wellcome Trust and the
409 MRC (grant 102215/2/13/2). The funders had no role in the study design, data collection, data
410 analysis nor preparation of the manuscript or decision to publish.

411

412 **AUTHOR CONTRIBUTIONS**

413 Conceptualisation, AF NJT LW AH LR; Methodology, HEB MS OF EM EO REM AT AH;
414 Validation, HEB MS OF EM EO AT AF; Formal Analysis, HEB MS OF REM MK AH; Investigation,
415 HEB MS OF EM KE EO BH DD AT BM; Resources, KG NDB PK AB IB AMT; Data Curation, KN

416 FR; Writing – Original Draft, HEB MS LW AH LR; Writing – Review and Editing, OF EO REM PK
417 AG AF NJT; Visualisation, HEB MS OF; Supervision, AMT IB AD AG AF LW AH LR; Project
418 Administration, JO SR LM LW AH LR; Funding Acquisition, AF SR LM NJT LW AH LR

419

420

421 **DECLARATION OF INTERESTS**

422 Adam Finn was a lead investigator on trials of COVID-19 vaccines funded by
423 Oxford/Astrazeneca, Valneva and Sanofi and the UK government. He also leads a University of
424 Bristol sponsored epidemiological study of adult respiratory disease funded by Pfizer which has
425 evaluated COVID-19 vaccine effectiveness. During the pandemic he was a member of the Joint
426 Committee on Vaccination and Immunisation which advised the UK government on COVID-19
427 vaccine policy and of the WHO Specialist Advisory Group of Experts COVID-19 vaccine working
428 group. No other authors declare competing interests.

429

430

431

432 **Figure 1: Study design**

433 (A) Participants from the Avon Longitudinal Study of Parents and Children (ALSPAC) were
434 screened for SARS-CoV-2-specific anti-Spike IgG in October 2020, prior to the vaccine rollout.
435 Both the G0 (48-70 years) and G1 (29-30 years) generations were eligible for screening. Further
436 sampling was conducted in June 2021 and June 2022 for both anti-Spike and anti-N IgG.
437 Numbers indicate the total valid tests, with the percentages indicating the positivity rates.

438

439 (B) Of those tested in October 2020, 377 were recruited to this study and attended one or more
440 clinics from December 2020 to June 2021, providing biological samples, and completing health
441 questionnaires. During this period, participants became eligible to receive COVID-19 vaccines
442 via the UK national vaccination programme (blue text indicates % vaccinated at each clinic).

443 Following the sampling period, participants continued to complete online questionnaires detailing
444 their LFT and PCR-confirmed SARS-CoV-2 infections.

445

446

447 **Figure 2: Antibody and T-cell responses to COVID-19 vaccination in SARS-CoV-2 naïve**
448 **and previously infected individuals.**

449 (A) Participants were classified as cases based on a previous PCR-confirmed SARS-CoV-2
450 infection and/or positivity on serum anti-Spike and/or anti-Nucleocapsid pan Ig ELISAs. (B)
451 Serum pseudoneutralising antibody titres. (C/D) Anti-Spike IgG and IgA in serum and saliva,
452 measured by ELISA. Correlation coefficients calculated using Spearman's rank (r_s). (E)
453 Magnitude of SARS-CoV-2-specific T-cell responses against Spike-1, Spike-2, N, M and NSP3B
454 peptide pools measured by ELISpot assay.

455

456 Red bars indicate median responses. Unpaired comparisons were performed using Kruskal-
457 Wallis test with Dunn's correction for multiple comparisons. Within each of the case and control
458 groups, responses were compared between 0 and 1, and 1 and 2 vaccine doses. Responses
459 between groups were compared after each dose. Statistics are only displayed for comparisons
460 where $P \leq 0.05$ (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

461

462

463 **Figure 3: SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cell responses in previously infected**
464 **individuals.**

465 Graphs show the percentage of CD4⁺ (A) and CD8⁺ (B) T-cells producing the indicated cytokine
466 or combination of cytokines after a brief stimulation with Spike-1, Spike-2, M, N or NSP3B peptide
467 pools, assessed by intracellular cytokine staining and flow cytometry. Pie charts indicate the
468 proportion of T-cells, within total cytokine⁺ T-cells, that producing each cytokine (colour-coded)
469 and that display one or more functions (black/grey). Statistics from monofunctional SARS-CoV-
470 2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals were calculated using a

471 Kruskal-Wallis test with FDR method of Benjamini and Hochberg correction
472 for multiple comparisons. P-values are reported in Table S2.

473

474

475 **Figure 4: Association between immune responses to prior SARS-CoV-2 infection and**
476 **COVID-19 vaccination and susceptibility to SARS-CoV-2 breakthrough infection**

477 (A/B) Correlation of post-second vaccination antibody and T-cell responses in participants who
478 self-reported a SARS-CoV-2 infection in the subsequent 8-months (breakthrough infection; BI)
479 and those who didn't (no BI). (A) SARS-CoV-2-naïve individuals (with BI n=14; no BI n=19). (B)
480 Previously SARS-CoV-2-infected individuals (BI n=8, no BI n=18). See Figure S10 for derivation
481 of thresholds.

482

483 (C-F) Correlation of pre-vaccination SARS-CoV-2-specific T-cell intracellular cytokine responses
484 in cases with subsequent BI. (C/D) Magnitude of baseline (pre-vaccination) single
485 cytokine/CD107a-producing (monofunctional) SARS-CoV-2-specific CD4⁺ (C; n=47) and CD8⁺
486 (D; n=51) T-cells specific for the indicated SARS-CoV-2 proteins among cases. Red bars
487 represent median responses. Statistics calculated by t-test (Mann-Whitney). (E/F) Proportions of
488 single cytokine/CD107a-producing CD4⁺ (n=40) and CD8⁺ (n=43) T-cells within the respective
489 M-specific T-cell population.

490

491

492

493 **METHODS**

494 ***ALSPAC***

495 The Avon Longitudinal Study of Parents and Children (ALSPAC) is a birth cohort study ⁷³⁻⁷⁶.
496 Pregnant women resident in Avon, UK with expected dates of delivery between 1st April 1991
497 and 31st December 1992 were invited to take part. A total of 14,541 pregnancies were initially
498 enrolled, with 13,988 children who were alive at 1 year of age. ALSPAC now comprises three

499 generations: the original pregnant women with the biological fathers and other carers/partners
500 (G0), the cohort of index children (G1), and the offspring of the index children (G2). This has
501 generated a wealth of biological, genetic and phenotypic data spanning the lifetime of these
502 individuals. Including additional participants recruited in the interim period, the total sample size
503 for analyses using any data collected after the age of seven is 15,447 pregnancies, resulting in
504 15,658 fetuses. Of these 14,901 children were alive at 1 year of age. 12,113 G0 partners have
505 been in contact with the study, of which 3,807 are currently enrolled. Please note that the study
506 website contains details of all the data that are available through a fully searchable data dictionary
507 and variable search tool ⁷⁷. From the beginning of the COVID-19 pandemic, ALSPAC sought to
508 utilise their unique expertise and infrastructure to contribute to SARS-CoV-2 research efforts
509 through collection of biological samples and questionnaire data from their cohort of well
510 characterised participants.

511

512 **Study design**

513 In October 2020, ALSPAC undertook 5200 serological SARS-CoV-2 spike-specific lateral flow
514 tests (Fortress Diagnostics, Antrim Northern Ireland) on G0 and G1 cohort participants ⁷⁸.
515 Participants with evidence of a previous SARS-CoV-2 infection based on a positive IgG result on
516 this LFT, and/or a positive SARS-CoV-2 PCR result from linked UK Health Security Agency
517 (UKHSA) data, were invited to take part in the study (n=124). Two control groups with negative
518 serological results, and no documented positive PCR test, were recruited alongside these
519 participants. The first control group (n=93) were also age, sex, and symptom (anosmia) matched
520 to those with a history of SARS-CoV-2 infection. Participants in the second control group (n=103)
521 were selected on the basis of not having reported anosmia. Full details of the recruitment
522 methodology, alongside a detailed characterisation of the cohort at clinic 1 (pre-vaccination), are
523 described in Mitchell *et al* ³⁰. In brief, participants attended up to 3 clinics in December 2020
524 (clinic 1), March 2021 (clinic 2) and June 2021 (clinic 3) where they provided venous blood and
525 saliva samples. Additional participants were recruited at clinics 2 and 3 to maintain numbers and
526 account for those who withdrew from the study. Health and lifestyle information was gathered

527 through online questionnaires. For the purposes of the analyses presented in this study, the two
528 control groups have been combined as no significant differences in baseline antibody or T-cell
529 measures were detected between the two original groups ³⁰.

530

531 ***Ethics***

532 Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and
533 the Local Research Ethics Committees (NHS REC 20/HRA/4854). Consent for biological
534 samples was collected in accordance with the Human Tissue Act (2004). Informed consent for
535 the use of data collected via questionnaires and clinics was obtained from participants following
536 the recommendations of the ALSPAC Ethics and Law Committee at the time.

537

538 At age 18, study children were sent 'fair processing' materials describing ALSPAC's intended use
539 of their health and administrative records and were given clear means to consent or object via a
540 written form. Data were not extracted for participants who objected, or who were not sent fair
541 processing materials. Ethical approval was obtained from the ALSPAC Law and Ethics
542 committee and local research ethics committees (NHS Haydock REC 10/H1010/70).

543

544 ***Sample collection and processing***

545 Peripheral blood mononuclear cells (PBMCs) were obtained from up to 3 x 10 ml EDTA tubes
546 per participant using standard density gradient separation techniques. Briefly, samples were kept
547 at room temperature for up to 3 hours after drawing blood. Blood was diluted 1:1 with Phosphate
548 Buffered Saline (PBS) containing 1% Fetal calf serum (FCS). Diluted blood was separated using
549 a Ficoll gradient, centrifuging at 1000g for 10 mins at room temperature. PBMCs were washed
550 in PBS/1% FCS, centrifuging at 700g for 10 mins at room temperature, and washed again with
551 PBS/1% FCS, centrifuging at 400g for 10 mins at room temperature. Cell pellets were
552 resuspended in freezing mix (90% FCS/10% DMSO) at a concentration of 13-15x10⁶ cells per
553 mL. Cells were frozen overnight in an alcohol bath to control freezing rate. PBMCs were then
554 transferred to liquid nitrogen cryotanks for long-term storage. Serum tubes were left to clot,

555 centrifuged at 1,500g for 10 mins at 18-25°C, then serum was removed, aliquoted, and stored at
556 -80 °C.

557

558 Participants provided neat saliva directly into a sterile collection tube. Particulate matter was
559 removed by centrifugation at 13,000g for 10 minutes. Samples were heat-inactivated at 56°C for
560 30 minutes prior to ELISA analysis.

561

562 ***ELISAs***

563 SARS-CoV-2-specific anti-Spike (S) IgA and IgG in serum and saliva were measured by ELISA.
564 Samples were run in duplicate at a single optimised dilution and reported in BAU/mL following
565 calibration of an internal standard to the WHO/NIBSC reference control. Serum anti-nucleocapsid
566 (N) and anti-S pan Ig were utilised as screening ELISAs to report a positive/negative result for
567 previous SARS-CoV-2 infection with data presented as normalised optical density (OD)
568 measurement relative to an internal control. Thresholds for positivity were calculated on a large
569 sample of PCR-confirmed and pre-pandemic samples. Full details of these methods are
570 published for serum ⁷⁹, and saliva ⁸⁰, respectively.

571

572 ***Synthetic peptides***

573 Peptides used for PBMC stimulations in the ELISpot assays are listed in Supplementary Table
574 S1. 15-mer peptides overlapping by 10 amino acids and spanning the sequences of the SARS-
575 CoV-2 S, N, Membrane (M) and Envelope (E) protein were purchased from Mimotopes
576 (Australia). The purity of the peptides was >80%. 15-18mer peptides overlapping by 10 amino
577 acids and spanning sequences of SARS-CoV-2 NSP1-16, ORF3, ORF6, ORF7 and ORF8 were
578 also purchased). The purity of the peptides was ~70%. The combination of peptides and identity
579 of the peptide pools are described in Methods Table 1. For PBMC stimulation in ELISpot assays,
580 pools of a maximum of 127 peptides were added per well as follows: Spike was divided into 2
581 pools (S1; 126 peptides and S2; 127 peptides); for smaller peptide regions, peptides were
582 combined in the same peptide pools as follows: NSP1 and NSP2 (NSP1+2), NSP5 and NSP6

583 (NSP5+6), NSP15 and NSP16 (NSP15+16). All other peptides were pooled into one mixture and
584 tested in individual ELISpot wells.

585

586 ***Enzyme-linked immune absorbent spot assay (ELISpot)***

587 Human IFN- γ ELISpot assays were performed using a Human IFN- γ ELISpot BASIC kit
588 (Mabtech). MSIP4W10 PVDF plates (Millipore) were coated with capture antibody (mAb-1-D1K;
589 15 $\mu\text{g}/\text{mL}$) and incubated overnight at 4 $^{\circ}\text{C}$ in carbonate bicarbonate buffer (Sigma Aldrich).
590 Cryopreserved PBMC were thawed then rested at 37 $^{\circ}\text{C}/5\%$ CO_2 for 5-6 hours. Coated plates
591 were washed 5 times in sterile PBS and blocked for 1-2 hours using R10 medium (0.2 μm filtered
592 RPMI 1640 medium supplemented with 10 % FBS, 2 mM glutamine, penicillin ((100 units/ml) and
593 streptomycin (100 $\mu\text{g}/\text{ml}$)). 4×10^5 PBMCs were added to each well in the plate, with or without
594 peptide pools (as indicated) in a total assay volume of 100 μl in R10. PBMC incubated with R10
595 medium alone were used as negative (unstimulated) controls and were performed in duplicate.
596 Peptide pools spanning S1, S2, M, N, E, ORF1 (NSP1+2, NSP3A, NSP3B, NSP3C, NSP4,
597 NSP5+6, NSP7-11, NSP12A, NSP12B, NSP13, NSP14, NSP15+16), ORF3, ORF6, ORF7 and
598 ORF8 were used at a final concentration of 2 $\mu\text{g}/\text{ml}$. PBMCs from cases were tested against all
599 the above peptide pools, while PBMCs from controls were tested against the following peptide
600 pools only: S1, S2, M, N, NSP3B, NSP12A, NSP12B, NSP7-11, NSP13 and NSP15+16. PBMC
601 stimulated with anti-CD3 antibody (Mabtech, Mab CD3-2; final concentration 0.1% v/v) were used
602 as a positive control for each participant, with $1-4 \times 10^5$ PBMCs used per well. Positive control
603 and peptide stimulated wells were performed in singlet. Plates were incubated for 16-18 hours at
604 37 $^{\circ}\text{C}/5\%$ CO_2 then developed as per manufacturer's instructions. Developed plates were
605 protected from light and air-dried for 48 hours before image acquisition using a CTL ImmunoSpot
606 S6 Ultra-V Analyzer. Spot forming units (SFU) were calculated using the ImmunoSpot S6 Ultra-
607 V Analyzer Basic Count function after image acquisition using optimised counting parameters
608 that were applied across all participants. Spot counts were enumerated for each peptide pool by
609 subtraction of average background (calculated from duplicate unstimulated wells). Counts were
610 expressed as SFU per million (10^6) PBMC after multiplication by 2.5 following background

611 subtraction. Negative values after background subtraction were adjusted to zero ²⁹. Participants
612 were excluded if the spot count in unstimulated wells exceeded 95 SFU per million PBMC or if
613 no spots were observed in the positive control wells. Where spot formation was too dense to
614 accurately enumerate using standardised counting parameters (TNTC; too numerous to count),
615 affected wells were excluded unless contemporaneous assessment of IFN- γ production by flow
616 cytometry confirmed antigen specific response. In these cases, TNTC values were given the raw
617 value equivalent to the largest spot count accurately counted for a peptide pool (320 SFU per
618 well).

619

620 ***Intracellular Cytokine Staining (ICS)***

621 PBMCs were thawed and rested overnight in AIMV 2% FCS then incubated with or without
622 peptide pools from SARS-CoV-2 S1/S2, M, N, NSP3B (all 1 μ g/ml), or with PMA/ionomycin (PMA
623 10 ng/ml, ionomycin 100 ng/ml, Sigma-Aldrich) for 5 hr at 37°C in the presence of brefeldin A
624 (BD, 5 μ g/ml). To assess degranulation, anti CD107a-FITC antibody was added to the cells at
625 the beginning of the stimulation. Cells were stained with a viability dye Zombie Aqua (BioLegend)
626 for 10 min at room temperature and then with antibodies targeting surface markers (20 min 4°C,
627 diluted in PBS 1% BSA; Sigma-Aldrich). Cells were fixed overnight in eBioscience
628 Foxp3/Transcription factor fixation/permeabilization buffer (Invitrogen), and intracellular staining
629 was performed for detection intracellular cytokines, including IFN- γ , TNF- α , IL-2 and MIP1 β (30
630 min 4°C). Four samples were excluded from further CD4⁺ T-cell analysis due technical issues.
631 Data were acquired on a BD LSR Fortessa X20 and analysed using FlowJo software v10.8.1.
632 Results were obtained after subtraction of the values in the corresponding unstimulated well. A
633 complete list of antibodies is included in Methods Table 2. ICS was performed on samples from
634 69 individuals in the case group, selected based on having a detectable T-cell response by IFN-
635 γ ELISpot at baseline (i.e. clinic one) for at least one of the SARS-CoV-2 peptide pools tested
636 and for whom we had additional cryopreserved PBMC vials available at baseline.

637

638 ***Pseudoneutralisation***

639 Serum neutralisation was expected to positively correlate with levels of anti-Spike antibody
640 binding results. Accordingly, all samples from participants in the case group corresponding to
641 anti-Spike pan-Ig ELISA results above a normalised threshold of 0.5 were included. For
642 pseudovirus assays, Wuhan-Spike-harboured pseudovirus (luciferase-expressing vesicular
643 stomatitis virus, VSV-S-FLuc) was generated and used to assess serum antibody neutralisation
644 of VSV-S-FLuc entry into Vero ACE2 TMPRSS2 (VAT) cells as described previously⁷⁹. Briefly,
645 serum dilutions starting at 1/40 followed by eight 2.5-fold titrations were plated in triplicate in 96-
646 well plates, alongside three wells each of 1/25 dilutions of known neutralising and non-
647 neutralising controls (corresponding to 16,000 RLU of luminescence when mixed with VSV-S-
648 FLuc). WT Wuhan spike pseudotyped VSV was added to each well and incubated for an hour.
649 Well-mixtures were added to black, microscopy 96-well plates, seeded with 10,000 Vero ACE2
650 TMPRSS2 (VAT) cells per well. Luminescence measurements were taken 16 hours after
651 infection, using the ONE-Glo Luciferase Assay System.

652

653 ***Data analysis***

654 Study data were collected and managed using REDCap (Research Electronic Data Capture)
655 electronic data capture tools hosted at the University of Bristol. REDCap is a secure, web-based
656 software platform designed to support data capture for research studies⁸¹.

657

658 Participant data was excluded from the analysis if it was subsequently established that a
659 participant was vaccinated as part of an unlicensed COVID-19 vaccine trial prior to enrolment in
660 this study. In order to focus on the immune responses to COVID-19 vaccines, data was also
661 removed if no corresponding information provided on the COVID-19 vaccination status of the
662 participant at a particular clinic visit. Where a participant provided samples at more than one clinic
663 after a specified number of vaccine doses (including pre-vaccination), only the data from the
664 earliest sampling clinic was included in the analysis.

665

666 Statistical analyses were performed using R Studio (v4.3.0), and GraphPad Prism (version
667 10.01). Unpaired comparisons across multiple groups were done with the Kruskal-Wallis test with
668 Dunn's post-test for multiple comparisons. Pairwise correlations were assessed with Spearman's
669 rank-order correlation (r_s). Correlation coefficients were interpreted as: weak ($r_s=0.20-0.39$),
670 moderate ($r_s=0.40-0.59$), strong ($r_s=0.60-0.79$), or very strong ($r_s=0.80-1.00$). The following
671 adjusted P value thresholds were used for data visualisation: $P \leq 0.05$ (*), $P \leq 0.01$ (**), $P \leq 0.001$
672 (***), $P \leq 0.0001$ (****). To facilitate the presentation of data which included zero counts on log
673 scales, zero counts were plotted as 1 (or the minimum y axis baseline, if lower) for visualisation
674 purposes only – all statistical analyses were performed on the raw data values.

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692 **Table S1: Participant demographics**

693 To protect participant anonymity, specific values for counts fewer than 5 are not provided. Please
694 note that fields marked as < 5 may include zero.

695

696 **Table S2: Statistical comparison of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺**
697 **T-cells in previously infected individuals.**

698 Statistics from monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously
699 infected individuals as presented in Figure 3. Calculated using a Kruskal-Wallis test with FDR
700 method of Benjamini and Hochberg correction for multiple comparisons.

701

702 **Table S3: Characteristics of the infection susceptibility groups.**

703 Participants were classified as cases based on a PCR-confirmed SARS-CoV-2 infection prior to
704 their second vaccine dose, and/or positivity on the serum anti-Spike and/or anti-Nucleocapsid
705 protein pan Ig screening ELISAs at clinic 1 (prior to vaccination). In each of the case and controls
706 groups, participants were stratified into those who did and didn't self-report a SARS-CoV-2
707 infection in the 8 months after clinic 3 (July 2021 – March 2022).

708

709 Participants self-reported information on whether they identified as having a weakened immune
710 system / increased susceptibility to infection at the beginning of the pandemic (April 2020). Data
711 on behavioural modifications were collected at the end of the breakthrough infection monitoring
712 period (March 2022). Participants self-reported whether they felt they had been limiting their
713 social contacts prior to meeting friends or relatives, and whether they had been shopping online
714 rather than visiting stores.

715

716 **Supplementary Figure 1: Participants inclusion flowchart.**

717 All G0 (original mothers and partners) and G1 (offspring generation) ALSPAC participants were
718 eligible to voluntarily enrol in this study. Participant data was subsequently excluded from the
719 analysis if they reported a previous COVID-19 vaccination. In order to focus on the immune
720 responses to COVID-19 vaccines, data was also removed if there was no corresponding

721 information provided on the COVID-19 vaccination status of the participant at a particular
722 timepoint.

723

724 **Supplementary Figure 2: Anti-N pan Ig levels in control participants before and after**
725 **vaccine dose 1.**

726 Serum anti-Nucleocapsid (N) pan Ig antibody levels in serum were measured by in-house ELISA.
727 Results are presented as normalised OD relative to an internal control. Data shown represent all
728 participants classified as controls with data available both before and after the first vaccine dose
729 (n=95). Participants with a ≥ 2 -fold increase in N pan Ig levels from baseline to post-dose 1 are
730 highlighted in red (n=3). Responses before and after vaccination were compared using a Mann
731 Whitney test.

732

733 **Supplementary Figure 3: Correlation between SARS-CoV-2 Spike-specific serum IgG and**
734 **pseudoneutralising antibody levels.**

735 Anti-Spike IgG levels in serum were measured by in-house ELISA and reported in BAU/mL
736 following calibration of the assay to the WHO/NIBSC reference standard. Pseudoneutralising
737 antibody titres against ancestral Spike were measured in serum. Spearman's rank (r_s)
738 correlations were calculated at baseline (white; n=99), post dose 1 (grey; n=61) and post dose 2
739 (blue; n=49). P values were categorised as ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

740

741 **Supplementary Figure 4: Antibody and T cell responses by COVID-19 vaccination type.**

742 Participants were stratified based upon the type of COVID vaccine received; AstraZeneca
743 ChAdOx1 whole virion vaccine, or one of two mRNA-based vaccines (Pfizer/BioNtech BNT162b2
744 or Moderna mRNA-1273). All participants received homologous first and second doses. (A)
745 Antibody levels in serum and saliva were measured by in-house ELISA. Assay thresholds were
746 set using samples taken following recent SARS-CoV-2 infection and pre-pandemic controls to
747 achieve 99% specificity. Results are reported in binding antibody units (BAU)/mL following
748 calibration of the assay to the WHO/NIBSC reference standard. (B) Magnitude of SARS-CoV-2

749 specific T cell response against Spike (pool-1 and 2) peptide pools measured via ELISpot
750 assay. Shown are comparison of cells producing IFN- γ after stimulation of PBMCs with
751 overlapping peptides spanning the indicated proteins. Results are expressed as Spot Forming
752 Units (SPU) relative to 1×10^6 PBMCs after subtraction of average background (calculated from
753 duplicate unstimulated wells). Negative values after background subtraction were adjusted to
754 zero. Participants were excluded from the dataset due to high background (>95 SFU per million
755 PBMC). White = baseline measurement; grey = post vaccine dose 1; blue = post vaccine dose
756 2. Red bars represent the median of each group. Unpaired comparisons were performed using
757 Kruskal-Wallis test with Dunn's correction for multiple comparisons. Within each of the case and
758 control groups, responses were compared between 0 and 1, and 1 and 2 vaccine doses.
759 Responses between groups were compared after each dose. Statistics are only displayed for
760 comparisons where $P \leq 0.05$. P values were categorised as ≤ 0.05 (*), ≤ 0.01 (**), ≤ 0.001 (***),
761 ≤ 0.0001 (****).

762

763 **Supplementary Figure 5: Magnitude of T-cell response following COVID-19 vaccination**

764 Ex-vivo IFN- γ ELISpots showing the overall magnitude and breadth of effector T-cell responses
765 to SARS-CoV-2 proteins following vaccination. (A) Responses in cases (n=108), and (B)
766 responses in controls (n=132). Results are expressed as Spot Forming Units (SFU) per
767 1×10^6 PBMCs after subtraction of average background (calculated from duplicate unstimulated
768 wells). Red bars represent median T-cell responses. Structural proteins: Spike (S1 and S2), M,
769 N and E, non-structural: NSP1-2, NSP3A, NSP3B, NSP3C, NSP4, NSP5-6, NSP7-11, NSP12A,
770 NSP12B, NSP13, NSP14 and NSP15-16, and accessory proteins: ORF3, ORF6, ORF7 and
771 ORF8. Significance was determined using a Kruskal-Wallis test with Dunn's correction
772 for multiple comparisons; where $P \leq 0.05$ (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

773

774 **Supplementary Figure 6: Gating-strategy for the identification of SARS-CoV-2-reactive** 775 **cytokine producing CD4⁺ and CD8⁺ T-cells**

776 PBMCs were stimulated with SARS-CoV-2-overlapping-peptide-pools (Spike, M, N and NSP3B)
777 for 6h after overnight resting. The gating strategy for CD4⁺ and CD8⁺ T-cells is shown panel A.
778 Dot plots are representative of cytokine secretion by CD4⁺ T-cells (B) and CD8⁺ T-cells (C)
779 specific for the Membrane (M) protein. These cells were further analysed for the expression of
780 interleukin (IL) 2, interferon γ (IFN- γ), tumour necrosis factor (TNF α), MIP1 β and degranulation
781 (CD107a) (panel B/C). The unstained control and PMA/I stimulated sample were used as a
782 negative and positive control for ICS assay, respectively (D).

783

784 **Supplementary Figure 7: Frequency of monofunctional SARS-CoV-2-specific CD4⁺ and**
785 **CD8⁺ T-cells in previously infected individuals.**

786 Percentage of cytokine-producing T-cells was measured by intracellular cytokine staining and
787 flow cytometry. Shown are the percentages of monofunctional CD4⁺ (A) and CD8⁺ (B) T-cells
788 producing IFN- γ , TNF α IL-2, MIP1 β or CD107a (single positive for each) after stimulation with
789 the indicated SARS-CoV-2 peptide pools. Statistics were calculated using a Kruskal-Wallis test
790 with Dunn's correction for multiple comparisons; where $P \leq 0.05$ (*), ≤ 0.01 (**), ≤ 0.001 (***),
791 ≤ 0.0001 (****).

792

793 **Supplementary Figure 8: Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ and**
794 **CD8⁺ T-cells in previously infected individuals.**

795 (A-B) Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ (left panel) and CD8⁺ (right panel)
796 T-cells targeting peptide pools from Spike and non-Spike proteins (M, N and NSP3B). Statistics
797 were determined using a Kruskal-Wallis test with Dunn's correction for multiple comparisons. (C-
798 D) Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ (left panel) and CD8⁺ (right panel) T-
799 cells targeting SARS-CoV-2 peptide pools in individuals who experienced BI infection versus
800 those who did not. Red bars represent median responses. Statistics were calculated by t-
801 test (Mann-Whitney test).

802

803 **Supplementary Figure 9: Comparison of post-vaccination dose 2 antibody and T-cell**
804 **levels in participants with and without a reported SARS-CoV-2 breakthrough infection.**

805 Post-second vaccination immune responses in participants who self-reported a SARS-CoV-2
806 infection in the subsequent 8-months (breakthrough infection; BI) and those who did not (no
807 breakthrough infection). (A) SARS-CoV-2-naïve individuals with (n=14) or without (n=19) a BI.
808 (B) Previously SARS-CoV-2-infected individuals with (n=8) or without (n=18) a BI. Bars represent
809 the median response. Groups were compared using a Mann-Whitney test, with statistics
810 categorised as: $P > 0.05$ (ns), $P \leq 0.05$ (*), ≤ 0.01 (**), ≤ 0.001 (***), ≤ 0.0001 (****).

811

812 **Supplementary Figure 10: Breakthrough infection susceptibility threshold setting**

813 Participants with a history of SARS-CoV-2 infection were stratified into two groups based upon
814 whether they went on to be re-infected in the 8-month period after the study end date (had a
815 breakthrough infection: yes /no). Receiver Operator Characteristic (ROC) curves were plotted for
816 serum and saliva binding antibody measures (A), serum pseudoneutralising antibody (B), and
817 IFN- γ producing T-cells (C). Youden's index thresholds were then calculated for each individual
818 measure and are represented by the blue dotted lines on each graph. The sensitivity and
819 specificity parameters for each threshold are presented alongside 95% confidence intervals
820 calculated using the Wilson/Brown method. AUC; area under curve, SE; sensitivity, SP;
821 specificity. Yes BI (n=8), no BI (n=18).

822

823 **Supplementary Figure 11: Performance of combined thresholds for breakthrough**
824 **infection susceptibility.**

825 Participants with a history of SARS-CoV-2 infection were stratified into two groups based upon
826 whether they went on to be re-infected in the 8-month period after the study end date (had a
827 breakthrough infection, BI). Thresholds antibody and T-cell levels that were associated with
828 protection against breakthrough infection were calculated using the Youden's index method
829 (figure S10 for full derivation). Values represent the specificity (SP) and sensitivity (SE) estimates
830 for combinations of two individual thresholds.

831

832

833

834 REFERENCES

- 835 1. Fink, Gunther, Tediosi, F., and Felder, S. (2022). Burden of Covid-19 restrictions: National,
836 regional and global estimates. <https://doi.org/10.1016/j>.
- 837 2. Thompson, E.J., Williams, D.M., Walker, A.J., Mitchell, R.E., Niedzwiedz, C.L., Yang, T.C.,
838 Huggins, C.F., Kwong, A.S.F., Silverwood, R.J., Di Gessa, G., et al. (2022). Long COVID
839 burden and risk factors in 10 UK longitudinal studies and electronic health records. *Nat*
840 *Commun* 13. <https://doi.org/10.1038/s41467-022-30836-0>.
- 841 3. Richards, F., Kodjamanova, P., Chen, X., Li, N., Atanasov, P., Bennetts, L., Patterson, B.J.,
842 Yektashenas, B., Mesa-Frias, M., Tronczynski, K., et al. (2022). Economic Burden of
843 COVID-19: A Systematic Review. Preprint at Dove Medical Press Ltd,
844 <https://doi.org/10.2147/CEOR.S338225> <https://doi.org/10.2147/CEOR.S338225>.
- 845 4. Wang, H., Zeng, W., Kabubei, K.M., Rasanathan, J.J.K., Kazungu, J., Ginindza, S., Mtshali,
846 S., Salinas, L.E., McClelland, A., Buissonniere, M., et al. (2023). Modelling the economic
847 burden of SARS-CoV-2 infection in health care workers in four countries. *Nat Commun* 14.
848 <https://doi.org/10.1038/s41467-023-38477-7>.
- 849 5. Hu, F.H., Jia, Y.J., Zhao, D.Y., Fu, X.L., Zhang, W.Q., Tang, W., Hu, S.Q., Wu, H., Ge, M.W.,
850 Du, W., et al. (2023). Clinical outcomes of the severe acute respiratory syndrome
851 coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33
852 studies covering 6 037 144 coronavirus disease 2019–positive patients. Preprint at
853 Elsevier B.V., <https://doi.org/10.1016/j.cmi.2023.03.017>
854 <https://doi.org/10.1016/j.cmi.2023.03.017>.
- 855 6. Hu, B., Guo, H., Zhou, P., and Shi, Z.L. (2021). Characteristics of SARS-CoV-2 and COVID-
856 19. Preprint at Nature Research, <https://doi.org/10.1038/s41579-020-00459-7>
857 <https://doi.org/10.1038/s41579-020-00459-7>.
- 858 7. Rahman, Md.O., Kamigaki, T., Thandar, M.M., Haruyama, R., Yan, F., Shibamura-Fujiogi,
859 M., Khin Maung Soe, J., Islam, Md.R., Yoneoka, D., Miyahara, R., et al. (2023). Protection
860 of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron
861 subvariant: a systematic review and meta-analysis. *BMJ Open* 13, e076892.
862 <https://doi.org/10.1136/bmjopen-2023-076892>.
- 863 8. Feikin, D.R., Higdon, M.M., Abu-Raddad, L.J., Andrews, N., Araos, R., Goldberg, Y.,
864 Groome, M.J., Huppert, A., O'Brien, K.L., Smith, P.G., et al. (2022). Duration of
865 effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a
866 systematic review and meta-regression. *The Lancet* 399, 924–944.
867 [https://doi.org/10.1016/S0140-6736\(22\)00152-0](https://doi.org/10.1016/S0140-6736(22)00152-0).
- 868 9. Wu, N., Joyal-Desmarais, K., Ribeiro, P.A.B., Vieira, A.M., Stojanovic, J., Sanuade, C., Yip,
869 D., and Bacon, S.L. (2023). Long-term effectiveness of COVID-19 vaccines against
870 infections, hospitalisations, and mortality in adults: findings from a rapid living systematic
871 evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir Med* 11, 439–
872 452. [https://doi.org/10.1016/S2213-2600\(23\)00015-2](https://doi.org/10.1016/S2213-2600(23)00015-2).
- 873 10. Desantis, S.M., Yaseen, A., Hao, T., León-Novelo, L., Talebi, Y., Valerio-Shewmaker, M.A.,
874 Pinzon Gomez, C.L., Messiah, S.E., Kohl, H.W., Kelder, S.H., et al. (2023). Incidence and
875 Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 after
876 Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants.
877 *Journal of Infectious Diseases* 227, 1164–1172. <https://doi.org/10.1093/infdis/jiad020>.

- 878 11. Piñana, J.L., Vazquez, L., Calabuig, M., López-Corral, L., Martin-Martin, G., Villalon, L.,
879 Sanz-Linares, G., Conesa-Garcia, V., Sanchez-Salinas, A., Gago, B., et al. (2023). One-year
880 breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated
881 hematological patients. *Blood Cancer J* 13. <https://doi.org/10.1038/s41408-022-00778-3>.
- 882 12. Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M.,
883 Levin, E.G., Rubin, C., Indenbaum, V., et al. (2021). Covid-19 Breakthrough Infections in
884 Vaccinated Health Care Workers. *New England Journal of Medicine* 385, 1474–1484.
885 <https://doi.org/10.1056/nejmoa2109072>.
- 886 13. Aldridge, R.W., Yavlinsky, A., Nguyen, V., Eyre, M.T., Shrotri, M., Navaratnam, A.M.D.,
887 Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022). SARS-CoV-2 antibodies and
888 breakthrough infections in the Virus Watch cohort. *Nat Commun* 13.
889 <https://doi.org/10.1038/s41467-022-32265-5>.
- 890 14. Moss, P. (2022). The T cell immune response against SARS-CoV-2. Preprint at Nature
891 Research, <https://doi.org/10.1038/s41590-021-01122-w> <https://doi.org/10.1038/s41590-021-01122-w>.
- 893 15. Ma, H., Zeng, W., He, H., Zhao, D., Jiang, D., Zhou, P., Cheng, L., Li, Y., Ma, X., and Jin, T.
894 (2020). Serum IgA, IgM, and IgG responses in COVID-19. Preprint at Springer Nature,
895 <https://doi.org/10.1038/s41423-020-0474-z> <https://doi.org/10.1038/s41423-020-0474-z>.
- 896 16. Chia, W.N., Zhu, F., Ong, S.W.X., Young, B.E., Fong, S.W., Le Bert, N., Tan, C.W., Tiu, C.,
897 Zhang, J., Tan, S.Y., et al. (2021). Dynamics of SARS-CoV-2 neutralising antibody responses
898 and duration of immunity: a longitudinal study. *Lancet Microbe* 2, e240–e249.
899 [https://doi.org/10.1016/S2666-5247\(21\)00025-2](https://doi.org/10.1016/S2666-5247(21)00025-2).
- 900 17. Montague, B.T., Wipperfurth, M.F., Chio, E., Crow, R., Hooper, A.T., O'Brien, M.P., and
901 Simões, E.A.F. (2022). Elevated serum IgA following vaccination against SARS-CoV-2 in a
902 cohort of high-risk first responders. *Sci Rep* 12. <https://doi.org/10.1038/s41598-022-19095-7>.
- 904 18. Yang, Z.R., Jiang, Y.W., Li, F.X., Liu, D., Lin, T.F., Zhao, Z.Y., Wei, C., Jin, Q.Y., Li, X.M., Jia,
905 Y.X., et al. (2023). Efficacy of SARS-CoV-2 vaccines and the dose–response relationship
906 with three major antibodies: a systematic review and meta-analysis of randomised
907 controlled trials. *Lancet Microbe* 4, e236–e246. [https://doi.org/10.1016/S2666-5247\(22\)00390-1](https://doi.org/10.1016/S2666-5247(22)00390-1).
- 909 19. Maringer, Y., Nelde, A., Schroeder, S.M., Schuhmacher, J., Hörber, S., Peter, A., Karbach,
910 J., Jäger, E., and Walz, J.S. (2022). Durable spike-specific T cell responses after different
911 COVID-19 vaccination regimens are not further enhanced by booster vaccination.
- 912 20. Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R.,
913 Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for
914 COVID-19 vaccines. *Vaccine* 39, 4423–4428.
915 <https://doi.org/10.1016/j.vaccine.2021.05.063>.
- 916 21. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
917 K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are
918 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat*
919 *Med* 27, 1205–1211. <https://doi.org/10.1038/s41591-021-01377-8>.
- 920 22. Sheikh-Mohamed, S., Isho, B., Chao, G.Y.C., Zuo, M., Cohen, C., Lustig, Y., Nahass, G.R.,
921 Salomon-Shulman, R.E., Blacker, G., Fazel-Zarandi, M., et al. (2022). Systemic and
922 mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination
923 and are associated with protection against subsequent infection. *Mucosal Immunol* 15,
924 799–808. <https://doi.org/10.1038/s41385-022-00511-0>.
- 925 23. Goh, Y.S., Fong, S.-W., Hor, P.X., Loh, C.Y., Wang, B., Salleh, S.N.M., Ngoh, E.Z.X., Lee,
926 R.T.C., Poh, X.Y., Rao, S., et al. (2023). Variant-Specific IgA Protects Against Omicron
927 Infection. *J Infect Dis*. <https://doi.org/10.1093/infdis/jiad525>.
- 928 24. Havervall, S., Marking, U., Svensson, J., Greilert-Norin, N., Bacchus, P., Nilsson, P., Hober,
929 S., Gordon, M., Blom, K., Klingström, J., et al. (2022). Anti-Spike Mucosal IgA Protection

- 930 against SARS-CoV-2 Omicron Infection. *New England Journal of Medicine* 387, 1333–
931 1336. <https://doi.org/10.1056/NEJMc2209651>.
- 932 25. Zuo, J., Dowell, A.C., Pearce, H., Verma, K., Long, H.M., Begum, J., Aiano, F., Amin-
933 Chowdhury, Z., Hallis, B., Stapley, L., et al. (2021). Robust SARS-CoV-2-specific T cell
934 immunity is maintained at 6 months following primary infection. *Nat Immunol* 22, 620–
935 626. <https://doi.org/10.1038/s41590-021-00902-8>.
- 936 26. Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I.,
937 Graichen, L., Moldenhauer, A.S., Winkler, M.S., et al. (2022). The Omicron variant is
938 highly resistant against antibody-mediated neutralization: Implications for control of the
939 COVID-19 pandemic. *Cell* 185, 447-456.e11. <https://doi.org/10.1016/j.cell.2021.12.032>.
- 940 27. Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M.,
941 Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARS-
942 CoV-2 variant Delta to antibody neutralization. *Nature* 596, 276–280.
943 <https://doi.org/10.1038/s41586-021-03777-9>.
- 944 28. Loyal, L., Braun, J., Henze, L., Kruse, B., Dingeldey, M., Reimer, U., Kern, F., Schwarz, T.,
945 Mangold, M., Unger, C., et al. (2021). Cross-reactive CD4+ T cells enhance SARS-CoV-2
946 immune responses upon infection and vaccination. *Science* (1979) 374.
947 <https://doi.org/10.1126/science.abh1823>.
- 948 29. Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C.,
949 Gibbons, J.M., Le Bert, N., Tan, A.T., et al. (2022). Pre-existing polymerase-specific T cells
950 expand in abortive seronegative SARS-CoV-2. *Nature* 601, 110–117.
951 <https://doi.org/10.1038/s41586-021-04186-8>.
- 952 30. Mitchell et al (2024) (under review).
- 953 31. Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,
954 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and
955 extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* 184, 5699-5714.e11.
956 <https://doi.org/https://doi.org/10.1016/j.cell.2021.10.011>.
- 957 32. Shrotri, M., Fragaszy, E., Nguyen, V., Navaratnam, A.M.D., Geismar, C., Beale, S., Kovar, J.,
958 Byrne, T.E., Fong, W.L.E., Patel, P., et al. (2022). Spike-antibody responses to COVID-19
959 vaccination by demographic and clinical factors in a prospective community cohort study.
960 *Nat Commun* 13. <https://doi.org/10.1038/s41467-022-33550-z>.
- 961 33. Sano, K., Bhavsar, D., Singh, G., Floda, D., Srivastava, K., Gleason, C., Amoako, A.A., Andre,
962 D., Beach, K.F., Bermúdez-González, M.C., et al. (2022). SARS-CoV-2 vaccination induces
963 mucosal antibody responses in previously infected individuals. *Nat Commun* 13.
964 <https://doi.org/10.1038/s41467-022-32389-8>.
- 965 34. Azzi, L., Dalla Gasperina, D., Veronesi, G., Shallak, M., Ietto, G., Iovino, D., Baj, A.,
966 Gianfagna, F., Maurino, V., Focosi, D., et al. (2022). Mucosal immune response in
967 BNT162b2 COVID-19 vaccine recipients. <https://doi.org/10.1016/j>.
- 968 35. Alu, A., Chen, L., Yuquan, H.L., Tian, W.X., and Wei, X. (2022). Intranasal COVID-19
969 vaccines: From bench to bed-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>). *EBioMedicine* 76, 103841. <https://doi.org/10.1016/j>.
- 970 36. Mudd, P.A., Minervina, A.A., Pogorelyy, M. V., Turner, J.S., Kim, W., Kalaidina, E.,
971 Petersen, J., Schmitz, A.J., Lei, T., Haile, A., et al. (2022). SARS-CoV-2 mRNA vaccination
972 elicits a robust and persistent T follicular helper cell response in humans. *Cell* 185, 603-
973 613.e15. <https://doi.org/10.1016/j.cell.2021.12.026>.
- 974 37. Swanson li, P.A., Padilla, M., Hoyland, W., Mcglinchey, K., Fields, P.A., Bibi, S., Faust, S.N.,
975 Mcdermott, A.B., Lambe, T., Pollard, A.J., et al. (2021). AZD1222/ChAdOx1 nCoV-19
976 vaccination induces a polyfunctional spike protein-specific T H 1 response with a diverse
977 TCR repertoire.
- 978 38. Maringer, Y., Nelde, A., Schroeder, S.M., Schuhmacher, J., Hörber, S., Peter, A., Karbach,
979 J., Jäger, E., and Walz, J.S. (2022). Durable spike-specific T cell responses after different
980 COVID-19 vaccination regimens are not further enhanced by booster vaccination.
981

- 982 39. Rivino, L., Kumaran, E.A., Thein, T.-L., Too, C.T., Chih, V., Gan, H., Hanson, B.J., Wilder-
983 Smith, A., Bertoletti, A., Gascoigne, N.R.J., et al. Virus-specific T lymphocytes home to the
984 skin during natural dengue infection.
- 985 40. Kim, T.S., and Shin, E.C. (2019). The activation of bystander CD8+ T cells and their roles in
986 viral infection. Preprint at Springer Nature, <https://doi.org/10.1038/s12276-019-0316-1>
987 <https://doi.org/10.1038/s12276-019-0316-1>.
- 988 41. Messina, N.L., Zimmermann, P., and Curtis, N. (2019). The impact of vaccines on
989 heterologous adaptive immunity. Preprint at Elsevier B.V.,
990 <https://doi.org/10.1016/j.cmi.2019.02.016> <https://doi.org/10.1016/j.cmi.2019.02.016>.
- 991 42. Lee, H.G., Cho, M.Z., and Choi, J.M. (2020). Bystander CD4+ T cells: crossroads between
992 innate and adaptive immunity. Preprint at Springer Nature,
993 <https://doi.org/10.1038/s12276-020-00486-7> [https://doi.org/10.1038/s12276-020-](https://doi.org/10.1038/s12276-020-00486-7)
994 [00486-7](https://doi.org/10.1038/s12276-020-00486-7).
- 995 43. Kim, T.S., and Shin, E.C. (2019). The activation of bystander CD8+ T cells and their roles in
996 viral infection. Preprint at Springer Nature, <https://doi.org/10.1038/s12276-019-0316-1>
997 <https://doi.org/10.1038/s12276-019-0316-1>.
- 998 44. Di Genova, G., Savelyeva, N., Suchacki, A., Thirdborough, S.M., and Stevenson, F.K.
999 (2010). Bystander stimulation of activated CD4+ T cells of unrelated specificity following a
1000 booster vaccination with tetanus toxoid. *Eur J Immunol* *40*, 976–985.
1001 <https://doi.org/10.1002/eji.200940017>.
- 1002 45. Whiteside, S.K., Snook, J.P., Williams, M.A., and Weis, J.J. (2018). Bystander T Cells: A
1003 Balancing Act of Friends and Foes. Preprint at Elsevier Ltd,
1004 <https://doi.org/10.1016/j.it.2018.10.003> <https://doi.org/10.1016/j.it.2018.10.003>.
- 1005 46. Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J.,
1006 Munro, K., Cole, M., et al. (2022). Protection against SARS-CoV-2 after Covid-19
1007 Vaccination and Previous Infection. *New England Journal of Medicine* *386*, 1207–1220.
1008 <https://doi.org/10.1056/nejmoa2118691>.
- 1009 47. Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K.,
1010 Mendelson, E., Ziv, A., et al. (2021). Waning Immune Humoral Response to BNT162b2
1011 Covid-19 Vaccine over 6 Months. *New England Journal of Medicine* *385*, e84.
1012 <https://doi.org/10.1056/NEJMoa2114583>.
- 1013 48. Pérez-Alós, L., Armenteros, J.J.A., Madsen, J.R., Hansen, C.B., Jarlhelt, I., Hamm, S.R.,
1014 Heftdal, L.D., Pries-Heje, M.M., Møller, D.L., Fogh, K., et al. (2022). Modeling of waning
1015 immunity after SARS-CoV-2 vaccination and influencing factors. *Nat Commun* *13*, 1614.
1016 <https://doi.org/10.1038/s41467-022-29225-4>.
- 1017 49. Carabelli, A.M., Peacock, T.P., Thorne, L.G., Harvey, W.T., Hughes, J., de Silva, T.I.,
1018 Peacock, S.J., Barclay, W.S., de Silva, T.I., Towers, G.J., et al. (2023). SARS-CoV-2 variant
1019 biology: immune escape, transmission and fitness. Preprint at Nature Research,
1020 <https://doi.org/10.1038/s41579-022-00841-7> [https://doi.org/10.1038/s41579-022-](https://doi.org/10.1038/s41579-022-00841-7)
1021 [00841-7](https://doi.org/10.1038/s41579-022-00841-7).
- 1022 50. Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H.,
1023 Doolman, R., Asraf, K., et al. (2022). Superior immunogenicity and effectiveness of the
1024 third compared to the second BNT162b2 vaccine dose. *Nat Immunol* *23*, 940–946.
1025 <https://doi.org/10.1038/s41590-022-01212-3>.
- 1026 51. Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M.,
1027 Gilbert, S.C., Hirsch, I., et al. (2021). Correlates of protection against symptomatic and
1028 asymptomatic SARS-CoV-2 infection. *Nat Med* *27*, 2032–2040.
1029 <https://doi.org/10.1038/s41591-021-01540-1>.
- 1030 52. Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou,
1031 H., Houchens, C.R., Martins, K., Jayashankar, L., et al. (2022). Immune correlates analysis
1032 of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* (1979) *375*, 43–50.
1033 <https://doi.org/10.1126/science.abm3425>.

- 1034 53. Regev-Yochay, G., Lustig, Y., Joseph, G., Gilboa, M., Barda, N., Gens, I., Indenbaum, V.,
1035 Halpern, O., Katz-Likvornik, S., Levin, T., et al. (2023). Correlates of protection against
1036 COVID-19 infection and intensity of symptomatic disease in vaccinated individuals
1037 exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study. *Lancet*
1038 *Microbe* 4, e309–e318. [https://doi.org/10.1016/S2666-5247\(23\)00012-5](https://doi.org/10.1016/S2666-5247(23)00012-5).
- 1039 54. Gromowski, G.D., Cincotta, C.M., Mayer, S., King, J., Swafford, I., McCracken, M.K.,
1040 Coleman, D., Enoch, J., Storme, C., Darden, J., et al. (2023). Humoral immune responses
1041 associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US
1042 military population. *EBioMedicine* 94. <https://doi.org/10.1016/j.ebiom.2023.104683>.
- 1043 55. Painter, M.M., Johnston, T.S., Lundgreen, K.A., Santos, J.J.S., Qin, J.S., Goel, R.R.,
1044 Apostolidis, S.A., Mathew, D., Fulmer, B., Williams, J.C., et al. (2023). Prior vaccination
1045 promotes early activation of memory T cells and enhances immune responses during
1046 SARS-CoV-2 breakthrough infection. *Nat Immunol* 24, 1711–1724.
1047 <https://doi.org/10.1038/s41590-023-01613-y>.
- 1048 56. Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A.S., Brown, A., Moore,
1049 S.C., Stafford, L., Dobson, S.L., et al. (2023). CD4+ and CD8+ T cells and antibodies are
1050 associated with protection against Delta vaccine breakthrough infection: a nested case-
1051 control study within the PITCH study. *mBio* 14. <https://doi.org/10.1128/mbio.01212-23>.
- 1052 57. Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S.A., De Intinis, C., Fesi, F., Gizzi, K.,
1053 Macagno, M., Montone, M., et al. (2022). Memory CD8+ T cell diversity and B cell
1054 responses correlate with protection against SARS-CoV-2 following mRNA vaccination. *Nat*
1055 *Immunol* 23, 1445–1456. <https://doi.org/10.1038/s41590-022-01313-z>.
- 1056 58. Almendro-Vázquez, P., Chivite-Lacaba, M., Utrero-Rico, A., González-Cuadrado, C.,
1057 Laguna-Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N.,
1058 Folgueira, M.D., et al. (2022). Cellular and humoral immune responses and breakthrough
1059 infections after three SARS-CoV-2 mRNA vaccine doses. *Front Immunol* 13.
1060 <https://doi.org/10.3389/fimmu.2022.981350>.
- 1061 59. Goldberg, Y., Mandel, M., Bar-On, Y.M., Bodenheimer, O., Freedman, L.S., Ash, N., Alroy-
1062 Preis, S., Huppert, A., and Milo, R. (2022). Protection and Waning of Natural and Hybrid
1063 Immunity to SARS-CoV-2. *New England Journal of Medicine* 386, 2201–2212.
1064 <https://doi.org/10.1056/nejmoa2118946>.
- 1065 60. Abu-Raddad, L.J., Chemaitelly, H., Ayoub, H.H., Yassine, H.M., Benslimane, F.M., Al
1066 Khatib, H.A., Tang, P., Hasan, M.R., Coyle, P., Al Kanaani, Z., et al. (2021). Association of
1067 Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA
1068 Vaccination in Qatar. *JAMA* 326, 1930–1939. <https://doi.org/10.1001/jama.2021.19623>.
- 1069 61. Bowman, K.A., Stein, D., Shin, S., Ferbas, K.G., Tobin, N.H., Mann, C., Fischinger, S.,
1070 Sapphire, E.O., Lauffenburger, D., Rimoin, A.W., et al. (2022). Hybrid Immunity Shifts the
1071 Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. *mBio* 13.
1072 <https://doi.org/10.1128/mbio.01647-22>.
- 1073 62. Rodda, L.B., Morawski, P.A., Pruner, K.B., Fahning, M.L., Howard, C.A., Franko, N., Logue,
1074 J., Eggenberger, J., Stokes, C., Golez, I., et al. (2022). Imprinted SARS-CoV-2-specific
1075 memory lymphocytes define hybrid immunity. *Cell* 185, 1588-1601.e14.
1076 <https://doi.org/10.1016/j.cell.2022.03.018>.
- 1077 63. Carazo, S., Skowronski, D.M., Brisson, M., Barkati, S., Sauvageau, C., Brousseau, N., Gilca,
1078 R., Fafard, J., Talbot, D., Ouakki, M., et al. (2023). Protection against omicron (B.1.1.529)
1079 BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection
1080 among health-care workers with and without mRNA vaccination: a test-negative case-
1081 control study. *Lancet Infect Dis* 23, 45–55. [https://doi.org/10.1016/S1473-3099\(22\)00578-3](https://doi.org/10.1016/S1473-3099(22)00578-3).
- 1082
1083 64. Reynolds, C.J., Gibbons, J.M., Pade, C., Lin, K.-M., Muñoz Sandoval, D., Pieper, F., Butler,
1084 D.K., Liu, S., Otter, A.D., Joy, G., et al. Heterologous infection and vaccination shapes
1085 immunity against SARS-CoV-2 variants.

- 1086 65. Walls, A.C., Sprouse, K.R., Bowen, J.E., Joshi, A., Franko, N., Navarro, M.J., Stewart, C.,
1087 Cameroni, E., McCallum, M., Goecker, E.A., et al. (2022). SARS-CoV-2 breakthrough
1088 infections elicit potent, broad, and durable neutralizing antibody responses. *Cell* 185,
1089 872-880.e3. <https://doi.org/10.1016/j.cell.2022.01.011>.
- 1090 66. Bertoletti, A., Le Bert, N., Qui, M., and Tan, A.T. (2021). SARS-CoV-2-specific T cells in
1091 infection and vaccination. Preprint at Springer Nature, [https://doi.org/10.1038/s41423-](https://doi.org/10.1038/s41423-021-00743-3)
1092 021-00743-3 <https://doi.org/10.1038/s41423-021-00743-3>.
- 1093 67. Nguyen, T.H.O., Cohen, C.A., Rowntree, L.C., Bull, M.B., Hachim, A., Kedzierska, K., and
1094 Valkenburg, S.A. (2021). T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and
1095 Against Future Variants. Preprint at Frontiers Media S.A.,
1096 <https://doi.org/10.3389/fmed.2021.793102> <https://doi.org/10.3389/fmed.2021.793102>.
- 1097 68. Lo Tartaro, D., Paolini, A., Mattioli, M., Swatler, J., Neroni, A., Borella, R., Santacroce, E.,
1098 Di Nella, A., Gozzi, L., Busani, S., et al. (2023). Detailed characterization of SARS-CoV-2-
1099 specific T and B cells after infection or heterologous vaccination. *Front Immunol* 14.
1100 <https://doi.org/10.3389/fimmu.2023.1123724>.
- 1101 69. Kohler, P., Güsewell, S., Seneghini, M., Egger, T., Leal, O., Brucher, A., Lemmenmeier, E.,
1102 Möller, J.C., Rieder, P., Ruetti, M., et al. (2021). Impact of baseline SARS-CoV-2 antibody
1103 status on syndromic surveillance and the risk of subsequent COVID-19—a prospective
1104 multicenter cohort study. *BMC Med* 19. <https://doi.org/10.1186/s12916-021-02144-9>.
- 1105 70. Follmann, D., Janes, H.E., Buhule, O.D., Zhou, H., Girard, B., Marks, K., Kotloff, K.,
1106 Desjardins, M., Corey, L., Neuzil, K.M., et al. (2022). Antinucleocapsid Antibodies After
1107 SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-
1108 1273 COVID-19 Vaccine Efficacy Clinical Trial. *Ann Intern Med* 175, 1258–1265.
1109 <https://doi.org/10.7326/M22-1300>.
- 1110 71. Allen, N., Brady, M., Carrion Martin, A.I., Domegan, L., Walsh, C., Doherty, L., Riain, U.N.,
1111 Bergin, C., Fleming, C., and Conlon, N. (2021). Serological markers of SARS-CoV-2
1112 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural
1113 infection in vaccinated individuals. *Journal of Infection* 83, e9–e10.
1114 <https://doi.org/https://doi.org/10.1016/j.jinf.2021.08.012>.
- 1115 72. Williams, D.M., Hornsby, H.R., Shehata, O.M., Brown, R., Gallis, M., Meardon, N.,
1116 Newman, T.A.H., Plowright, M., Zafred, D., Shun-Shion, A.S.M., et al. (2023). Establishing
1117 SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via
1118 high-content microscopy. *iScience* 26. <https://doi.org/10.1016/j.isci.2023.107056>.
- 1119 73. Northstone, K., Ben Shlomo, Y., Teyhan, A., Hill, A., Groom, A., Mumme, M., Timpson, N.,
1120 and Golding, J. (2023). The Avon Longitudinal Study of Parents and children ALSPAC G0
1121 Partners: A cohort profile. *Wellcome Open Res* 8, 37.
1122 <https://doi.org/10.12688/wellcomeopenres.18782.1>.
- 1123 74. Fraser, A., Macdonald-wallis, C., Tilling, K., Boyd, A., Golding, J., Davey smith, G.,
1124 Henderson, J., Macleod, J., Molloy, L., Ness, A., et al. (2013). Cohort profile: The avon
1125 longitudinal study of parents and children: ALSPAC mothers cohort. *Int J Epidemiol* 42,
1126 97–110. <https://doi.org/10.1093/ije/dys066>.
- 1127 75. Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness,
1128 A., Ring, S., and Smith, G.D. (2013). Cohort profile: The 'Children of the 90s'-The index
1129 offspring of the avon longitudinal study of parents and children. *Int J Epidemiol* 42, 111–
1130 127. <https://doi.org/10.1093/ije/dys064>.
- 1131 76. Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., and Wells, N.
1132 (2019). The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the
1133 enrolled sample of index children in 2019. *Wellcome Open Res* 4.
1134 <https://doi.org/10.12688/wellcomeopenres.15132.1>.
- 1135 77. ALSPAC data dictionary <http://www.bristol.ac.uk/alspac/researchers/our-data/>.
- 1136 78. Northstone, K., Smith, D., Bowring, C., Hill, A., Hobbs, R., Wells, N., and Timpson, N.J.
1137 (2021). The Avon Longitudinal Study of Parents and Children - A resource for COVID-19

1138 research: Home-based antibody testing results, October 2020. Wellcome Open Res 6.
1139 <https://doi.org/10.12688/wellcomeopenres.16616.1>.
1140 79. Halliday, A., Long, A.E., Baum, H.E., Thomas, A.C., Shelley, K.L., Oliver, E., Gupta, K.,
1141 Francis, O., Williamson, M.K., Di Bartolo, N., et al. (2022). Development and evaluation of
1142 low-volume tests to detect and characterize antibodies to SARS-CoV-2. *Front Immunol*
1143 *13*. <https://doi.org/10.3389/fimmu.2022.968317>.
1144 80. Thomas, A.C., Oliver, E., Baum, H.E., Gupta, K., Shelley, K.L., Long, A.E., Jones, H.E., Smith,
1145 J., Hitchings, B., di Bartolo, N., et al. (2023). Evaluation and deployment of isotype-
1146 specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children
1147 and adults. *Communications Medicine* 3, 37. [https://doi.org/10.1038/s43856-023-00264-](https://doi.org/10.1038/s43856-023-00264-2)
1148 [2](https://doi.org/10.1038/s43856-023-00264-2).
1149 81. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009).
1150 Research electronic data capture (REDCap)-A metadata-driven methodology and
1151 workflow process for providing translational research informatics support. *J Biomed*
1152 *Inform* 42, 377–381. <https://doi.org/10.1016/j.jbi.2008.08.010>.
1153




Figure 1: Study design.





Figure 2: Antibody and T-cell responses to COVID-19 vaccination in SARS-CoV-2 naïve and previously infected individuals.






Figure 4: Association between immune responses to prior SARS-CoV-2 infection and COVID-19 vaccination and susceptibility to SARS-CoV-2 breakthrough infection.

Table S1: Participant demographics


	Cases (N=199)	Controls (N=176)
Sex		
Female / male (n)	142 / 57	80 / 96
Age		
G0 / G1 (n)	77 / 122	79 / 98
Mean age (years)	39	42
Median age (years)	29	29
Age unknown (n)	22	0
Ethnicity		
Asian/Asian British (n)	< 5	< 5
Black/African/ Caribbean/ Black British (n)	< 5	< 5
Arab or other ethnic group (n)	< 5	< 5
Mixed/multiple ethnic groups (n)	< 5	< 5
White (n)	≥ 166	≥ 144
Ethnicity data not available (n)	8	9

Table S2: Statistical comparison of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.


Cytokines	Protein	Individual P Value / Monofunctional CD4 ⁺ T-cells	Individual P Value / Monofunctional CD8 ⁺ T-cells
MIP1 β vs IL2	S1	0.0966	<0.0001
	S2	0.1297	<0.0001
	M	>0.9999	<0.0001
	N	0.0146	<0.0001
	NSP3B	0.0658	<0.0001
MIP1 β vs CD107a	S1	0.0074	<0.0001
	S2	0.5881	<0.0001
	M	<0.0001	<0.0001
	N	0.08	<0.0001
	NSP3B	0.9148	<0.0001
MIP1 β vs IFN γ	S1	0.0227	<0.0001
	S2	0.0034	<0.0001
	M	0.0003	<0.0001
	N	0.0134	<0.0001
	NSP3B	0.208	<0.0001
MIP1 β vs TNF α	S1	<0.0001	0.007
	S2	<0.0001	0.002
	M	<0.0001	<0.0001
	N	<0.0001	<0.0001
	NSP3B	<0.0001	0.0011
IL2 vs CD107a	S1	0.3092	0.0492
	S2	0.0397	0.6678
	M	<0.0001	0.0015
	N	0.4888	0.3673
	NSP3B	0.0832	0.9519
IL2 vs IFN γ	S1	<0.0001	0.1972
	S2	<0.0001	0.0309
	M	<0.0001	0.0295
	N	<0.0001	0.0381
	NSP3B	0.0019	0.4588
IL2 vs TNF α	S1	<0.0001	<0.0001
	S2	<0.0001	<0.0001
	M	<0.0001	0.002
	N	<0.0001	0.0002
	NSP3B	<0.0001	<0.0001
CD107a vs IFN γ	S1	<0.0001	0.0011
	S2	0.0171	0.0837
	M	>0.9999	0.3141
	N	<0.0001	0.0029
	NSP3B	0.1719	0.4961
CD107a vs TNF α	S1	<0.0001	<0.0001
	S2	<0.0001	<0.0001
	M	0.1842	0.9218
	N	<0.0001	<0.0001
	NSP3B	<0.0001	<0.0001
IFN γ vs TNF α	S1	<0.0001	0.005
	S2	<0.0001	0.0113
	M	0.0566	0.3636
	N	0.0001	0.1086
	NSP3B	0.002	0.0004

Table S3: Characteristics of the infection susceptibility groups.


	Cases		Controls	
	Breakthrough infection	No breakthrough infection	Breakthrough infection	No breakthrough infection
Total (n)	8	18	14	19
Proportion of group reinfected (%)	30.8%	/	42.4%	/
Triple vaccinated before infection (%)	75.0%	/	78.6%	/
COVID-19 vaccines dose 1&2 = mRNA (%)	75.0%	44.4%	14.3%	21.1%
Days since vaccine dose 2 (median; IQR)	50 (31-71)	40 (29-54)	50 (42-59)	41 (26-49)
Female (%)	100%	72.2%	71.4%	78.9%
G0 generation (%)	37.5%	83.3%	100%	100%
Reported having a weakened immune system	0.0%	5.6%	0.0%	0.0%
Limited contacts before meeting friends / relatives	50.0%	22.2%	50.0%	36.8%
Shopped online rather than visiting shops	20.0%	11.1%	35.7%	31.6%



Supplementary Figure 1: Participants inclusion flowchart.




Supplementary Figure 2: Anti-N pan Ig levels in control participants before and after vaccine dose 1.




Supplementary Figure 3: Correlation between SARS-CoV-2 Spike-specific serum IgG and pseudoneutralising antibody levels.

A




B




Supplementary Figure 4: Antibody and T cell responses by COVID-19 vaccination type.


A





B




Supplementary Figure 5: Magnitude of T-cell response following COVID-19 vaccination



Supplementary Figure 6: Gating-strategy for the identification of SARS-CoV-2-reactive cytokine producing CD4⁺ and CD8⁺ T-cells


A**B**

Supplementary Figure 7: Frequency of monofunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.




Supplementary Figure 8: Frequency of polyfunctional SARS-CoV-2-specific CD4⁺ and CD8⁺ T-cells in previously infected individuals.

A




B




Supplementary Figure 9: Comparison of post-vaccination dose 2 antibody and T-cell levels in participants with and without a reported SARS-CoV-2 breakthrough infection.

A




<p>AUC = 0.8194</p> <p>Threshold > 1.042</p> <p>SE = 77.78 (54.79% to 91.00%)</p> <p>SP = 75.0 (40.93% to 95.56%)</p>	<p>AUC = 0.8958</p> <p>Threshold > 0.2245</p> <p>SE = 88.89 (67.20% to 98.03%)</p> <p>SP = 87.5 (52.91% to 99.36%)</p>	<p>AUC = 0.9306</p> <p>Threshold > 666.4</p> <p>SE = 94.44 (74.24% to 99.72%)</p> <p>SP = 87.5 (52.91% to 99.36%)</p>	<p>AUC = 0.7917</p> <p>Threshold > 386.6</p> <p>SE = 72.22 (49.13% to 87.50%)</p> <p>SP = 87.5 (52.91% to 99.36%)</p>	<p>AUC = 0.8194</p> <p>Threshold > 0.547</p> <p>SE = 94.44 (74.24% to 99.72%)</p> <p>SP = 75.0 (40.93% to 95.56%)</p>	<p>AUC = 0.6389</p> <p>Threshold > 4.873</p> <p>SE = 66.67 (43.75% to 83.72%)</p> <p>SP = 62.5 (30.57% to 86.32%)</p>
--	---	--	--	--	--

B



<p>AUC = 0.7847</p> <p>Threshold > 6165</p> <p>SE = 61.11 (38.62% to 79.69%)</p> <p>SP = 100.0 (67.56% to 100.0%)</p>
--

C




<p>AUC = 0.7708</p> <p>Threshold > 195.6</p> <p>SE = 72.2 (49.13% to 87.50%)</p> <p>SP = 87.5 (52.91% to 99.36%)</p>

<p>AUC = 0.7083</p> <p>Threshold > 226.3</p> <p>SE = 66.67 (43.75% to 83.72%)</p> <p>SP = 75.0 (40.93% to 95.56%)</p>
--

<p>AUC = 0.5972</p> <p>Threshold > 45.63</p> <p>SE = 38.89 (20.31% to 61.38%)</p> <p>SP = 87.5 (52.91% to 99.36%)</p>
--

Supplementary Figure 10: Breakthrough infection susceptibility Youden's index threshold setting



Supplementary Figure 11: Performance of combined thresholds for breakthrough infection susceptibility.